Maternal serum bisphenol A levels and risk of pre-eclampsia: a nested case–control study

Yunzhen Ye[1,2], Qiongjie Zhou[1,2,3], Liping Feng[4], Jiangnan Wu[1], Yu Xiong[1,2], Xiaotian Li[1,2,5,6]

1 Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China
2 The Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Shanghai, China
3 Women's Health and Perinatology Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromso, Norway
4 Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
5 The Shanghai Key Laboratory of Birth Defects, Shanghai, China
6 Institute of Biochemical Sciences, Fudan University, Shanghai, China

Yu Xiong and Xiaotian Li contributed equally to this study.

Correspondence: Yu Xiong, Obstetrics and Gynecology Hospital of Fudan University, Shengyang Road 128, Yangpu District, Shanghai, China. Postcode: 200030, Tel:+86(0) 21- 33189900-6357, Fax: 021-55122025, e-mail: xiongyu1535@163.com

Background: Although recent studies have indicated the potential adverse effects of maternal bisphenol A (BPA) exposure on pregnancy such as increasing the risk of pre-eclampsia, epidemiological evidence is limited. We aimed to evaluate the relationship between maternal BPA exposure and the risk of pre-eclampsia. **Methods:** We conducted a nested case–control study among 173 women (74 cases of pre-eclampsia and 99 controls). BPA concentrations were measured using liquid chromatography-mass spectrometry in the maternal serum samples collected during 16–20 gestational weeks. Multivariate logistic models were used to examine the relationship between maternal serum BPA concentrations and the risk of pre-eclampsia. **Results:** BPA was detectable (>0.1 μg/l) in 78.6% of the maternal serum samples at three levels: low (<2.24 μg/l), medium (2.24-4.44 μg/l), and high (>4.44 μg/l). BPA concentrations were significantly higher in the serum samples collected from the pre-eclampsia cases than those from controls (median: 3.40 vs. 1.50 μg/l, $P < 0.01$). With adjustment for maternal age, primiparous and BMI, the odds of developing pre-eclampsia were significantly elevated in subjects with high serum BPA levels compared with those with low levels (adjusted OR = 16.46, 95%CI = 5.42–49.85) regardless of subcategories of pre-eclampsia including severity and onset time. Among the pre-eclampsia subjects, the maternal serum concentration of BPA was not different between the early- and late-onset subjects (median: 3.09 vs. 3.50 μg/l, $P = 0.57$), but surprisingly higher in mild pre-eclampsia subjects compared with severe pre-eclampsia subjects (median: 5.20 vs. 1.80 μg/l, $P < 0.01$). **Conclusions:** These results demonstrated that maternal exposure to high level of BPA could be associated with an increased risk of pre-eclampsia.

Introduction

Pre-eclampsia, a new-onset hypertension disorder that occurs after the 20th week of pregnancy and is characterized by proteinuria and multisystem damage, affecting 2–8% of pregnancies worldwide.[1] Pre-eclampsia is one of the leading causes of maternal mortality and morbidity and accounts for 30–35% of preterm births.[1] Although the aetiology of pre-eclampsia remains elusive, endocrine dysregulation is considered a possible contributor to pathogenesis of this disease[2,3]; thus, maternal exposure to endocrine disrupting chemicals (EDCs) can be a potential risk factor of pre-eclampsia. However, this research area is understudied.

Bisphenol A (BPA), one of the most studied EDCs, is a man-made chemical widely utilized in the production of epoxy resins and polycarbonate polymers and exists in various consumer products such as water bottles, metal coating, flooring materials and thermal papers.[4] BPA can be easily released from these products, resulting in ubiquitous human exposure[5] primarily through diet.[6,7] Oral intake of BPA could result in elevated serum BPA levels in does–effect relationship in mice.[8] Previous studies have demonstrated that BPA could accumulate in the placenta[9,10] and induce toxic effects in placental cells[11–13] which are potentially associated with abnormal placental development and subsequent pregnancy

outcomes such as pre-eclampsia. However, current epidemic evidence for the association between maternal BPA exposure and pre-eclampsia is limited.[14,15] It was found that pre-eclampsia women showed increased BPA concentrations in placenta at delivery[15]and in urinary samples at early pregnancy[14] comparing with normotensive controls, but data of BPA exposure as an influence on maternal serum level is lacking. The objective of the present study was to examine the relationship between maternal BPA exposure and risk of pre-eclampsia. We hypothesized that maternal exposure to BPA could be associated with an increased risk of pre-eclampsia. To test our hypothesis, we designed a nested case–control study between pre-eclampsia cases and healthy term controls. Maternal serum concentrations of BPA in mid-pregnancy were compared between cases and controls. We calculated the odds ratio for having a pregnancy complicated with pre-eclampsia in subjects with high, medium levels of serum BPA compared with subjects with low levels of serum BPA.

Methods

Study design and data source

Eligible subjects were women with singleton pregnancies who had records of serum samples collected during 16–20 gestational weeks

and later delivered at the Obstetrics and Gynecology Hospital of Fudan University from 2013 to 2014. Medical history was abstracted from subject's medical records. Cases were subjects who diagnosed with pre-eclampsia. Pre-eclampsia subjects complicated with diabetes mellitus were excluded. Mild pre-eclampsia and severe pre-eclampsia were diagnosed according to the 2013 ACOG guidelines.[16] Briefly, pre-eclampsia was defined as blood pressures ≥140 mmHg systolic or ≥90 mmHg diastolic after 20 weeks of gestation along with positive urinary protein testing (300 mg/24 h). Pre-eclampsia was regarded severe cases in the setting of higher blood pressure (SBP ≥160 mmHg or DBP ≥90 mmHg) and/or serious proteinuria (≥5 g/24 h) accompanied with organ dysfunction. Early onset pre-eclampsia was cases that were diagnosed before 34 gestational weeks and late-onset pre-eclampsia were cases that were diagnosed after 34 gestational weeks. Healthy controls were randomly selected among full-term pregnancy mothers who had serum samples collected in the similar seasons and year according to pre-eclampsia cases and who did not experience major congenital foetal anomalies, chronic hypertension, kidney disease, diabetes mellitus, or any other significant pre-existing chronic disease. Gestational age was estimated according to the reported last menstruation period (LMP) or ultrasound in the first trimester if foetal size and LMP did not match. The diagnoses of all subjects were verified by the principal study investigators. The demographic information was obtained by searching the Hospital Information System including maternal age, weight, height and education level. Maternal weight was recorded at the first prenatal visit, and the body mass index (BMI) was calculated was weight divided by height squared (kg/m²).

Of the total cohort of 9464 pregnant women, 252 cases of pre-eclampsia (2.66%) were identified. After excluding 40 multi-pregnancy cases and 53 gestational diabetes mellitus, 159 pre-eclampsia cases were confirmed, half of which (80 cases) were randomly selected for further analysis based on the power calculation ($6\,2 = 2*[(Z_\alpha + Z_\beta)\sigma/\delta]^2$; $\delta = 0.48$ µg/l, $\sigma = 0.91$ µg/l, $\alpha = 0.05$, $\beta = 0.10$).[14–17] To have slightly more control than cases, 100 healthy controls were randomly selected. A total of 7 serum samples (3.89%) (6 cases and 1 control) were missing and were thus removed from further analysis (74 cases vs. 99 controls; figure 1).

The study protocol was approved by the Ethics Committee of the Gynecology and Obstetrics Hospital of Fudan University. The methods were performed in accordance with the approved guidelines of STROBE.[18] Our study was qualified as an exemption for obtaining informed consent from the participants because serum samples were originally scrap (out of medical use and otherwise discarded) and further analysis was conducted in a way which would not compromise personal privacy.

Sample collection

At regular prenatal visit during 16–20 gestational weeks, a maternal spot, non-fasting blood sample was obtained using 5 ml plain tube (polyethylene terephthalate) without additive (Kangjian medical, Jiangsu, China) and temporarily stored at 4 °C within 8 h. Blood samples were then centrifuged at 3000 rpm at 4 °C for 15 min and serum was collected and stored at −20 °C in 12 × 75 mm polyethylene tube (Kangjian medical, Jiangsu, China.) until further analysis. All serum samples were identified on the same day and were transported on dry ice to Microspectrum Technology Corporation, Shanghai, China for BPA measurement.

Laboratory analysis

The coded samples were sent blindly to the laboratories. Only free BPA but not conjugated BPA was measured because conjugated BPA varies significantly among individuals due to their variable metabolic ability[19] and because free BPA has been reported to be the biologically active form.[6] Serum free BPA was measured by liquid chromatography-mass spectrometry (LC-MS) (Acquity TQD) as previously described in Ref. 20 with some modifications. Briefly, the samples were processed in glass tubes and subjected to liquid phase extraction by n-hexane and ether in a ratio of 7:3 for three times, then dried by Nitrogen in 40 °C water bath and the eluent was reconstituted with methanol for LC-MS analysis. The LC separation was performed using the ACQUITY UPLC C18 column (1.7 µm, 2.1 × 50 mm) with a gradient elution system of 1% ammonia solution, and methanol was used as the mobile phase. Mass spectrometry analyser was used for the qualitative and quantitative analysis of LC-MC system. The linearity was obtained at range from 0.1–100 µg/l with correlation coefficient of more than 0.999. The limit of BPA detection was 0.1 µg/l. BPA levels below the limit of detection (LOD) were kept if a number value was reported; otherwise, a value was assigned by dividing the LOD (0.1 µg/l) by two, if no number value was reported. The repeatability and recovery of the method were assessed by repeated samples analysis ($n = 3$). The standard error ranged from 0 to 0.495. The average recovery rate was 107.7%.

Statistical analysis

Statistical analyses were performed using SPSS 20.0, and the statistical threshold for significance was set as 0.05. Data of maternal characteristics were analysed using basic descriptive statistics, such as the Student's *t*-test for continuous variables and then χ^2 or Fisher' exact test for categorical variables. The distribution of serum BPA concentrations was tested by the Kolmogorov-Smirnov normality test, and it was found to be skewed and log-transform did not change this status. A Mann–Whitney U test was used to compare the differences in serum BPA concentrations between cases and controls. To examine the association between serum BPA concentration and the risk of developing pr-eeclampsia, multivariate logistic regression models were performed by calculating the unadjusted (Model 1) and adjusted odd ratios (ORs) (Model 2) and their 95% CI. In the adjusted model, variables including maternal age, parity and BMI were retained in the model, regardless of statistical significance, because they have been reported to be associated with pre-eclampsia[21]; other variables were included in the adjusted model if they altered the association between BPA concentration and pre-eclampsia by >10%. Similar regressions were conducted to examine the association between maternal serum BPA concentrations and the risk of developing each subcategory of pre-eclampsia including mild, severe, early- and late-onset pre-eclampsia. For the sensitivity analysis, additional models were run when superimposed pre-eclampsia was excluded.

To explore the effects of BPA on pre-eclampsia at different exposure levels, and the potential for non-linear relationships, we grouped the study subjects into low, medium, and high level based on the optimal point of the ROC analysis where optimal consistence (sensitivity + specifity−1) was get at this point. Unadjusted and adjusted ORs of pre-eclampsia were calculated by comparing subjects with medium or high BPA levels respectively with subjects with low BPA levels in logistic regression models. Additionally, we conducted a Log-rank survival analysis to explore the cumulative incidences of pre-eclampsia among different BPA levels with the progress of pregnancy. The research period ranged through pregnancy. The occurrence of pre-eclampsia was considered an end event. Complete data included the pregnancy age of women in whom pre-eclampsia occurred, and censored data included the pregnancy age of those who did not develop pre-eclampsia.

Results

General characteristics

Table 1 summarized the general characteristics of all participants. Maternal age ranged from 19 to 39 years with a mean of 29.20 (SD =3.52 years). The majority had a normal BMI ($n = 113$; 68.48%),

Figure 1 Study profile. ∗GMD was excluded, because it was reported to be associated with insulin resistance

education above college ($n = 150$; 87.72%), and primiparous ($n = 155$; 89.60%). Among all infants, 52% ($n = 89$) were boys and 48% ($n = 82$) were girls. A higher proportion of mothers in the pre-eclampsia group was overweight (BMI $\geq$ 25) compared with control group (27.14% vs. 10%; $P < 0.01$). The gestational age in the pre-eclampsia group was less than that of controls (mean $\pm$SD: 37.73 ± 3.05 vs. 39.13 ± 1.23 gestational weeks; $P < 0.01$). The pre-eclampsia group and the control group did not differ in maternal age, maternal educational status, infant sex distribution or the percentage of mothers who were primiparous. Maternal serum samples were collected at similar gestation ages (cases vs. controls: 16.83 ± 1.94 vs. 16.77 ± 1.52 gestational weeks; $P = 0.81$) and seasons ($P = 0.51$). The storage time of serum samples did not differ between cases and controls (mean $\pm$ SD: 623 ± 121.89 vs. 651.00 ± 151.61 days; $P = 0.21$), which eliminated effects of container BPA contamination during the storage period.

Maternal serum BPA concentrations

Maternal serum concentrations of BPA were below LOD in 37 samples (21.4%; 30 controls and 7 cases). The median (25th, 75th) maternal serum BPA concentration in all subjects was 2.30 µg/l (0.05–3.93 µg/l; data not showed).

Associations between maternal BPA exposure and pre-eclampsia

Significantly higher maternal serum BPA concentrations were observed in pre-eclampsia cases compared with controls (median: 3.40 vs. 1.50 µg/l; $P < 0.01$) (table 2). Significantly elevated odds of pre-eclampsia with each unit increase in BPA concentrations (unadjusted OR = 1.43; 95% CI = 1.24, 1.67) was observed and this effect was slightly attenuated after adjusted for maternal age, BMI and parity (adjusted OR =1.19; 95% CI = 1.19, 1.63) (table 2). In the subset analysis, all subsets of pre-eclampsia had significantly

higher serum BPA concentrations than controls ($P < 0.01$) (table 2). Interestingly, among pre-eclampsia subjects, significantly higher BPA concentrations were observed in mild-pre-eclampsia cases compared with severe-pre-eclampsia cases (median: 5.20 vs. 1.80 µg/l; $P < 0.01$) (Supplementary table S1). No significant difference was observed in BPA concentrations between early- and late-onset pre-eclampsia cases (median: 3.09 vs. 3.50 µg/l; $P = 0.57$) (Supplementary table S1).

As a sensitivity analysis, we ran additional models after excluding cases of superimposed pre-eclampsia ($n = 12$) (Supplementary table S2). Intriguingly, greater ORs for pre-eclampsia associated with each unit increase of BPA were observed (adjusted OR = 1.48; 95%CI = 1.25, 1.75) (Supplementary table S2).

In the ROC analysis (Supplementary figure S1), BPA exposure showed good performance as a predictor of pre-eclampsia (AUC = 0.73; 95% CI = 0.65–0.81). When the BPA concentrations were divided into three levels, 2.24 and 4.44 were selected as the intercept points because they had an optimal consistency (0.34 = sensitivity + specifity−1) in the ROC curve, resulting in low (<2.24 µg/l), medium (2.24–4.44 µg/l), and high (>4.44 µg/l) BPA level. At high BPA level, there was significantly higher proportion of pre-eclampsia than the control (39.2 vs. 5.1%; $P < 0.01$) (table 3). The odds of pre-eclampsia were significantly elevated in subjects with high serum BPA level compared with those with low levels (unadjusted OR = 17.12; 95% CI = 5.87–49.94) (table 3) and this positive trend retained after adjusting for maternal age, parity and maternal BMI (adjusted OR = 16.46; 95% CI = 5.42–49.95) (table 3). No significant relationship was found between subjects with medium BPA level and those with low BPA level in adjusted model (adjusted OR = 2.15; 95% CI = 0.98–4.75) (table 3).

In the survival analysis, both subjects with medium and high serum BPA levels tended to significantly have a higher cumulative incidence and an earlier onset time of pre-eclampsia compared with

Table 1 General characteristics of 173 mothers

Variables	Total (*n* = 173) Mean ± SD or *n* (%)	Controls (*n* = 99) Mean ± SD or *n* (%)	Cases (*n* = 74) Mean ± SD or *n* (%)	*P*-value[a]
Maternal age (years)	29.20 ± 3.52	28.92 ± 3.73	29.57 ± 3.20	0.23
BMI at first visit (kg/m²)				<0.01
<18.5 (underweight)	24 (14.55)	20 (20.20)	4 (5.72)	
18.5–24.99(normal weight)	113 (68.48)	66 (66.67)	47 (67.14)	
>25 (overweight)	28 (16.97)	10 (10.10)	19 (27.14)	
Education				0.54
<College	21 (12.28)	11 (11.22)	10 (13.70)	
College	142 (83.04)	81 (81.65)	61 (83.56)	
>College	8 (4.68)	6 (6.12)	2 (2.74)	
Primiparous (%)	155 (89.60)	87 (87.88)	68 (91.89)	0.39
Gestational age at delivery (weeks)	38.53 ± 2.30	39.13 ± 1.23	37.73 ± 3.05	<0.01
Infant sex				0.54
Female	82 (47.95)	45 (45.45)	37 (50.68)	
Male	89 (52.05)	53 (53.54)	36 (49.32)	
Gestational weeks at serum collection	16.79 ± 1.71	16.77 ± 1.52	16.83 ± 1.94	0.81
Season of blood collection				0.51
Spring	45 (26.01)	23 (23.23)	22 (29.73)	
Summer	40 (23.12)	26 (26.26)	14 (18.92)	
Fall	49 (28.32)	26 (26.26)	23 (30.08)	
Winter	39 (22.54)	24 (24.24)	15 (20.27)	
Storage time of samples (day)	639.41 ± 140.04	651.00 ± 151.61	623 ± 121.89	0.21

a: Cases were compared with controls.

Table 2 ORs (95% CIs) of pre-eclampsia subcategories associated with serum BPA concentrations

		n	BPA concentration (μg/l) median (25th, 75th)	Model 1[a] Unadjusted OR (95% CI)	*P*-value	Model 2[a] Adjusted OR (95% CI)[b]	*P*-value
Controls		99	1.50 (0.05, 1.98)	1		1	
Cases		74	3.40 (1.85, 6.73)	1.43 (1.24, 1.67)	<0.01	1.39 (1.19, 1.63)	<0.01
Severity	Mild	46	5.20 (2.96, 7.17)	1.47 (1.25-1.73)	<0.01	1.42 (1.21-1.67)	<0.01
	Severe	28	1.80 (0.48, 2.94)	1.38 (1.17-1.64)	<0.01	1.35 (1.14-1.60)	<0.01
Onset time[c]	Early onset	12	3.09 (2.28, 4.94)	1.35 (1.08, 1.70)	<0.01	1.33 (1.07-1.66)	<0.01
	Late onset	59	3.50 (1.70, 6.80)	1.48 (1.26, 1.73)	<0.01	1.41 (1.20-1.66)	<0.01

a: Pre-eclampsia subsets were separately compared with controls by logistic regression.
b: Adjusted for maternal age, parity and BMI.
c: One case of severe pre-eclampsia lacked information regarding the gestational week in which pre-eclampsia was diagnosed and was therefore considered missing; two cases of pre-eclampsia superimposed on chronic hypertension were excluded.

Table 3 ORs (95% CIs) for the onset of pre-eclampsia associated with BPA levels

BPA level[a] (μg/l)	Controls *n* (%)	Pre-eclampsia *n* (%)	Unadjusted OR (95% CI)[b]	*P*-value	Adjusted OR (95% CI)[b,c]	*P*-value
Low (<2.24)	62 (62.6)	21 (28.4)	1.00		1.00	
Medium (2.24–4.44)	32 (32.3)	24 (32.4)	2.21 (1.07–4.57)	0.03	2.15 (0.98–4.75)	0.06
High (>4.44)	5 (5.1)	29 (39.2)	17.12 (5.87–49.94)	<0.01	16.46 (5.42–49.95)	<0.01

a: BPA level was determined according to the cut-off point for optimal consistency (0.34) of the ROC curve.
b: When compared with the lowest BPA level by logistic regression.
c: Adjusted for maternal age, primiparous and BMI.

those with low BPA level ($P < 0.05$ for medium level; $P < 0.01$ for high level) (Supplementary figure S2).

Discussion

Key findings and significance

To the best of our knowledge, this is the first study to investigate maternal serum BPA in mid-pregnancy in relation to pre-eclampsia. We found that women who developed pre-eclampsia experienced significantly higher levels of BPA exposure during 16–20 gestational weeks regardless of its subcategories including severity and onset time. Among the subjects with pre-eclampsia, the maternal serum BPA concentrations were not different between the early- and late-onset groups, and were significantly higher in the mild subjects compared with the severe subjects. Our study provided new evidence for the potential risk of maternal BPA exposure on pre-eclampsia. The major path of exposure to BPA is through diet, and behavioural changes, such as using BPA-free products, could potentially reduce the degree of exposure. Thus behaviour interventions to reduce maternal BPA exposure might reduce the risk of pre-eclampsia. Understanding the role of maternal BPA exposure in pregnancy outcomes is essential to answering important public health questions about the reproductive toxicities of this emerging

environment pollutant, thus providing scientific basis for exposure reduction policies.

Comparisons

Our results underscore the previously identified relationship between BPA exposure and increased risk of pre-eclampsia. A case–control study[15] of women reported elevated BPA concentrations in placentas of pre-eclampsia women, but not maternal or cord serum at delivery, compared with normotensive controls. Other researchers revealed significantly increased odds of pre-eclampsia in association with urinary BPA concentrations at 10 weeks gestation, while urinary BPA was assessed several times during pregnancy.[14] In our current study, BPA concentrations were measured in serum samples collected during the first half of pregnancy, a window coincides with placental development.[22] Results from all three studies strongly suggested that maternal exposure to BPA is a risk factor for developing pre-eclampsia. We further speculated that timing of exposure to BPA is critical for its adverse effects on pre-eclampsia and maternal exposure at the first half pregnancy is riskier than the second half of pregnancy. Further evidences are needed to confirm this assumption.

Interpretations

Although the specific pathophysiology of pre-eclampsia is unclear, poor placentation plays a crucial role in the development of pre-eclampsia. In humans, placentation occurs during the first half of pregnancy as trophoblastic invasion remodels the narrow-lumen, muscle spiral arteries into dilated, low-resistance utero-placental vessels.[23] Any factors that cause defective trophoblastic remodelling during early pregnancy could result in placental dysfunction following dysregulating angiogenic profiles, which play crucial roles in the development of pre-eclampsia. Free BPA can pass through the placental barrier and accumulate in the placenta,[9,10] and BPA exposure can result in the degeneration and necrosis of placental cells and disturb angiogenesis both *in vitro* and *in vivo*.[11–13] BPA was also reported to be associated with increased circulating sFLT–1/PLGF ratio during pregnancy, an antiangiogenic status in pre-eclampsia.[24] Additionally, the Comparative Toxicogenomics Database shows top 10 BPA interacting genes, many of which were reported to affect trophoblastic migration, invasion and apoptosis abilities,[25–29] including MAPK, caspases and BCL2.[30] In our current study, we found an increased risk of pre-eclampsia related to BPA exposure during 16–20 gestational weeks (mean = 16.8), a window that is susceptible to various factors that may result in defective placental development.[23] To our surprise, we found that mild-pre-eclampsia women had significantly higher serum BPA concentrations than severe-pre-eclampsia women. Although we do not have a definitive explanation for this observation, we think it is because of the complexity of pathogenesis of pre-eclampsia. For instance, severe pre-eclampsia subjects may be more susceptible to BPA exposure because of existing pre-dispositions for pre-eclampsia such as genetic predisposition.[31,32] Or other risk factors appeared to play much more prominent roles in the development of severe pre-eclampsia than BPA exposure. Nevertheless, further *in vivo* experiments are necessary to determine the causal relationship of maternal exposure of BPA and pre-eclampsia and to investigate its possible pathological mechanisms.

Strengths and limitations

Strengths of our study are that BPA exposure was determined before the onset of pre-eclampsia and that serum samples were used to directly reflect the exposure levels.

There were some limitations in our study. First, there were some shortages in blood sample collection and storage. In this study, all the blood samples were collected from women who underwent regular prenatal visit with the same laboratory consumables under conventional processes. Though we could not dismiss completely the

possibilities of contamination during the processes of sample collection and processing, we tried our best to eliminate the difference of contamination degree between the case and controls as much as possible. In this way, we chose controls among whose sample was collected from the similar season in the same year compared with the case group to eliminate different effects of temperature and storage time on container BPA release status. Furthermore, in later analysis process, all the samples were set blindly to the laboratories and to be treated in standard procedures. Finally, serum BPA concentrations reported in our study is similar to previous reports.[15,33–35] Therefore, the BPA levels in our study, to a great extent, are comparable between the cases and controls. Second, we measured the BPA concentrations at one time point, which may not accurately reflect the exposure status, as an interclass correlation coefficient of 0.32 was reported for BPA, although this result did present within-person variability.[36] However, other reports have suggested that a single BPA concentration measurement can accurately reflect one's exposure status by classifying the patient into different exposure levels[37] because the lifestyle and living environment of one person do not change readily. Third, we were unable to obtain the maternal smoking status for our cohort, even though the behaviour has been demonstrated to be inversely related to pre-eclampsia.[38,39]

Conclusions

In conclusion, we found that maternal serum BPA in first half of pregnancy was significantly related to an increased risk of pre-eclampsia, thus providing a potential approach to pre-eclampsia prevention by reducing BPA exposure during pregnancy. Further studies are needed to understand the relationship between BPA exposure and the risk of pre-eclampsia in pregnant women.

Supplementary data

Supplementary data are available at *EURPUB* online.

Acknowledgements

Key points

- This the first study to measure bisphenol A (BPA) levels in maternal serum samples in first half of pregnancy in relation to pre-eclampsia.
- This nested-case control study showed that pre-eclampsia women had significantly higher levels of BPA exposure during 16–20 gestational weeks and that highest level of

BPA exposure was associated with a significantly increased risk of pre-eclampsia.
- Our study provided new evidence for the potential risk of BPA exposure on pre-eclampsia and provided clues to preventing pre-eclampsia.

References

1 Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* 2009;33:130–7.

2 Widmer M, Villar J, Benigni A. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. *Obstet Gynecol* 2007;109:168–80.

3 Phipps E, Prasanna D, Brima W, et al. Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. *Clin J Am Soc Nephrol* 2016;11:1102–13.

4 Bisphenol A (BPA) - Current State of Knowledge and Future Actions by WHO and FAO | Canadian Partnership for Children's Health and Environment. Available at: http://www.healthyenvironmentforkids.ca/resources/BPA-knowledge-future-actions-who-fao (19 October 2015, date last accessed).

5 Vandenberg LN, Hauser R, Marcus M, et al. Human exposure to bisphenol A (BPA). *Reprod Toxicol* 2007;24:139–77.

6 Michałowicz J. Bisphenol A–sources, toxicity and biotransformation. *Environ Toxicol Pharmacol* 2014;37:738–58.

7 WHO. Toxicological and health aspects of bisphenol A. Availabe at: http://www.who.int/foodsafety/publications/bisphenol-a/en/ (18 July 2017, date last accessed).

8 Petzold S, Averbeck M, Simon JC, et al. Lifetime-dependent effects of bisphenol A on asthma development in an experimental mouse model. *PLoS One* 2014;9:e100468.

9 Schonfelder G, Wittfoht W, Hopp H, et al. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. *Environ Health Perspect* 2002;110:A703–7.

10 Corbel T, Gayrard V, Puel S, et al. Bidirectional placental transfer of Bisphenol A and its main metabolite, Bisphenol A-Glucuronide, in the isolated perfused human placenta. *Reprod Toxicol* 2014; 47:51–8.

11 Benachour N, Aris A. Toxic effects of low doses of Bisphenol-A on human placental cells. *Toxicol Appl Pharmacol* 2009;241:322–8.

12 Tait S, Tassinari R, Maranghi F, et al. Bisphenol A affects placental layers morphology and angiogenesis during early pregnancy phase in mice. *J Appl Toxicol* 2015;35:1278–91.

13 Wang ZY, Lu J, Zhang YZ, et al. Effect of Bisphenol A on invasion ability of human trophoblastic cell line BeWo. *Int J Clin Exp Pathol* 2015;8:14355–64.

14 Cantonwine DE, Meeker JD, Ferguson KK, et al. Urinary Concentrations of Bisphenol A and Phthalate Metabolites Measured during Pregnancy and Risk of Preeclampsia. *Environ Health Perspect* 2016;124:1651–55.

15 Leclerc F, Dubois MF, Aris A. Maternal, placental and fetal exposure to bisphenol A in women with and without preeclampsia. *Hypertens Pregnancy* 2014;33:341–8.

16 Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists' task force on hypertension in pregnancy. *Obstet Gynecol* 2013;122:1122–31.

17 Arbuckle TE, Marro L, Davis K, et al. Exposure to free and conjugated forms of bisphenol A and triclosan among pregnant women in the MIREC cohort. *Environ Health Perspect* 2015;123:277–84.

18 STROBE Statement: Home. Available at: https://www.strobe-statement.org/index.php? id=strobe-home (24 July 2017, date last accessed).

19 Volkel W, Colnot T, Csanady GA, et al. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. *Chem Res Toxicol* 2002;15:1281–7.

20 Jing X, Bing S, Xiaoyan W, et al. A study on bisphenol A, nonylphenol, and octylphenol in human urine amples detected by SPE-UPLC-MS. *Biomed Environ Sci* 2011;24:40–6.

21 Endeshaw M, Abebe F, Worku S, et al. Obesity in young age is a risk factor for preeclampsia: a facility based case-control study, northwest Ethiopia. *BMC Pregnancy Childbirth* 2016;16:237.

22 Hunkapiller NM, Fisher SJ. Chapter 12. Placental remodeling of the uterine vasculature. *Methods Enzymol* 2008;445:281–302.

23 Red-Horse K, Rivera J, Schanz A, et al. Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation. *J Clin Invest* 2006;116:2643–52.

24 Ferguson KK, McElrath TF, Cantonwine DE, et al. Phthalate metabolites and bisphenol-A in association with circulating angiogenic biomarkers across pregnancy. *Placenta* 2015;36:699–703.

25 Cohen M, Meisser A, Haenggeli L, et al. Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells. *Mol Hum Reprod* 2006;12:225–32.

26 Heazell AE, Buttle HR, Baker PN, et al. Altered expression of regulators of caspase activity within trophoblast of normal pregnancies and pregnancies complicated by preeclampsia. *Reprod Sci* 2008; 15:1034–43.

27 Jordan JA, Butchko AR. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody. *Placenta* 2002;23:547–53.

28 Perez-Perez A, Gambino Y, Maymo J, et al. MAPK and PI3K activities are required for leptin stimulation of protein synthesis in human trophoblastic cells. *Biochem Biophys Res Commun* 2010;396:956–60.

29 Zhang L, Jia L, Cui S, et al. AP-2alpha-dependent regulation of Bcl-2/Bax expression affects apoptosis in the trophoblast. *J Mol Histol* 2012;43:681–9.

30 Bisphenol A. CTD. Available at: http://ctdbase.org/detail.go? type=chem&acc=C006780 (18 July 2017, date last accessed).

31 Valenzuela FJ, Perez-Sepulveda A, Torres MJ, et al. Pathogenesis of preeclampsia: the genetic component. *J Pregnancy* 2012;2012:632732.

32 Serebrova VN, Trifonova EA, Gabidulina TV, et al. Detection of novel genetic markers of susceptibility to preeclampsia based on an analysis of the regulatory genes in the placental tissue. *Mol Biol (Mosk)* 2016;50:870–9.

33 He Y, Miao M, Herrinton LJ, et al. Bisphenol A levels in blood and urine in a Chinese population and the personal factors affecting the levels. *Environ Res* 2009;109:629–33.

34 Huo W, Xia W, Wan Y, et al. Maternal urinary bisphenol A levels and infant low birth weight: a nested case-control study of the Health Baby Cohort in China. *Environ Int* 2015;85:96–103.

35 Oppeneer SJ, Robien K. Bisphenol A exposure and associations with obesity among adults: a critical review. *Public Health Nutr* 2015;18:1847–63.

36 Snijder CA, Heederik D, Pierik FH, et al. Fetal growth and prenatal exposure to bisphenol A: the generation R study. *Environ Health Perspect* 2013;121:393–8.

37 Mahalingaiah S, Meeker JD, Pearson KR, et al. Temporal variability and predictors of urinary bisphenol A concentrations in men and women. *Environ Health Perspect* 2008;116:173–8.

38 Tong VT, Jones JR, Dietz PM, et al. Trends in smoking before, during, and after pregnancy - Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000-2005. *MMWR Surveill Summ* 2009;58:1–29.

39 Mackay DF, Nelson SM, Haw SJ, et al. *Impact of Scotland's Smoke-Free Legislation on Pregnancy Complications: Retrospective Cohort Study PLoS Med*, 2012;9:e1001175.